Terms: = Prostate cancer AND CALCB, Calcitonin AND Treatment
48 results:
1. Cold sensor, hot topic: TRPM8 plays a role in monocyte function and differentiation.
Trusiano B; Tupik JD; Allen IC
J Leukoc Biol; 2022 Sep; 112(3):361-363. PubMed ID: 35570407
[TBL] [Abstract] [Full Text] [Related]
2. Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw.
Schubert L; Russmueller G; Lagler H; Tobudic S; Heindel E; Kundi M; Steininger C
Support Care Cancer; 2021 Dec; 29(12):7895-7902. PubMed ID: 34189608
[TBL] [Abstract] [Full Text] [Related]
3. Neuronal calcitonin gene-related peptide promotes prostate tumor growth in the bone microenvironment.
Zhu W; Sheng D; Shao Y; Zhang Q; Peng Y
Peptides; 2021 Jan; 135():170423. PubMed ID: 33086087
[TBL] [Abstract] [Full Text] [Related]
4. The Prevention and Therapy of Osteoporosis: A Review on Emerging Trends from Hormonal Therapy to Synthetic Drugs to Plant-Based Bioactives.
Gupta T; Das N; Imran S
J Diet Suppl; 2019; 16(6):699-713. PubMed ID: 29985715
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults.
van den Blink QU; Garcez K; Henson CC; Davidson SE; Higham CE
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010604. PubMed ID: 29683475
[TBL] [Abstract] [Full Text] [Related]
6. Characterization of prostate cancer cell progression in zebrafish xenograft model.
Xu W; Foster BA; Richards M; Bondioli KR; Shah G; Green CC
Int J Oncol; 2018 Jan; 52(1):252-260. PubMed ID: 29115578
[TBL] [Abstract] [Full Text] [Related]
7. 223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
García Cañamaque L; Rioja Parada C; García De la Peña P
Tumori; 2017 Nov; 103(Suppl. 1):e53-e55. PubMed ID: 28525684
[TBL] [Abstract] [Full Text] [Related]
8. treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
Ramalingam S; Eisenberg A; Foo WC; Freedman J; Armstrong AJ; Moss LG; Harrison MR
Int J Urol; 2016 Dec; 23(12):1038-1041. PubMed ID: 27766686
[TBL] [Abstract] [Full Text] [Related]
9. Salmon calcitonin use and associated cancer risk.
Overman RA; Borse M; Gourlay ML
Ann Pharmacother; 2013 Dec; 47(12):1675-84. PubMed ID: 24259626
[TBL] [Abstract] [Full Text] [Related]
10. Hot flushes in healthy aging men differ from those in men with prostate cancer and in menopausal women.
Holm AC; Thorell LH; Theodorsson E; Hammar M
Gynecol Endocrinol; 2012 Jan; 28(1):72-5. PubMed ID: 21878036
[TBL] [Abstract] [Full Text] [Related]
11. Acupuncture for hot flashes in patients with prostate cancer.
Beer TM; Benavides M; Emmons SL; Hayes M; Liu G; Garzotto M; Donovan D; Katovic N; Reeder C; Eilers K
Urology; 2010 Nov; 76(5):1182-8. PubMed ID: 20494414
[TBL] [Abstract] [Full Text] [Related]
12. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.
Michaud LB
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S20-30; quiz S31-3. PubMed ID: 20332495
[TBL] [Abstract] [Full Text] [Related]
13. Significance of serum calcitonin gene-related peptide levels in prostate cancer patients receiving hormonal therapy.
Suzuki K; Kobayashi Y; Morita T
Urol Int; 2009; 82(3):291-5. PubMed ID: 19440016
[TBL] [Abstract] [Full Text] [Related]
14. Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.
Shah GV; Muralidharan A; Thomas S; Gokulgandhi M; Mudit M; Khanfar M; El Sayed K
Mol Cancer Ther; 2009 Mar; 8(3):509-20. PubMed ID: 19276166
[TBL] [Abstract] [Full Text] [Related]
15. calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways.
Shah GV; Thomas S; Muralidharan A; Liu Y; Hermonat PL; Williams J; Chaudhary J
Endocr Relat Cancer; 2008 Dec; 15(4):953-64. PubMed ID: 18784182
[TBL] [Abstract] [Full Text] [Related]
16. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer--a prospective multicenter study with long-term follow-up.
Frisk J; Spetz AC; Hjertberg H; Petersson B; Hammar M
Eur Urol; 2009 Jan; 55(1):156-63. PubMed ID: 18294761
[TBL] [Abstract] [Full Text] [Related]
17. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract] [Full Text] [Related]
18. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.
Yee EF; White RE; Murata GH; Handanos C; Hoffman RM
J Gen Intern Med; 2007 Sep; 22(9):1305-10. PubMed ID: 17634780
[TBL] [Abstract] [Full Text] [Related]
19. Serum calcitonin gene-related peptide levels in untreated prostate cancer patients.
Suzuki K; Kobayashi Y; Morita T
Int J Urol; 2006 Jun; 13(6):781-4. PubMed ID: 16834660
[TBL] [Abstract] [Full Text] [Related]
20. cancer-treatment-induced bone loss, part 2.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
[TBL] [Abstract] [Full Text] [Related]
[Next]
